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Size of Metastatic and Nonmetastatic Mediastinal Lymph
Nodes in Non-small Cell Lung Cancer
Koei Ikeda, MD, PhD, Hiroaki Nomori, MD, PhD, Takeshi Mori, MD, Hironori Kobayashi, MD,
Kazunori Iwatani, MD, and Kentaro Yoshimoto, MD
Objective: To determine the optimum selection of mediastinal
lymph nodes for biopsy in non-small cell lung cancer (NSCLC),
lymph nodes with or without metastasis at each mediastinal station
were ranked in size in patients with pathological N2 disease.
Methods: Twenty-five NSCLC patients with pathological N2 dis-
ease who underwent pulmonary resection with complete mediastinal
lymph node clearance were examined. Of 114 mediastinal lymph
node stations dissected, 47 had metastases and 67 did not. The sizes
of 259 nodes in the 47 positive lymph node stations were measured.
Of these 259 nodes, 137 had metastases and 122 did not. The short-
and long-axis diameters of the 259 lymph nodes were ranked in each
lymph node station.
Results: Mean short- and long-axis diameters of lymph nodes with
metastases were significantly greater than those without (p 0.001).
In 47 metastatic lymph node stations, the short- and long-axis
diameters were greatest in a metastatic node in 44 (94%) and 42
(89%) respectively, whereas in the remaining 3 (6%) and 5 (11%),
the second largest but not the largest node was positive. None of the
largest lymph nodes with metastasis were smaller than the second
largest lymph node at each station. Four of the 10 patients with
adenocarcinoma (40%) had metastasis in the second largest but not
in the largest node measured by long-axis diameter, a significant
difference from one in eight (12.5%) among the squamous cell
carcinoma cases (p  0.04).
Conclusion: For mediastinal lymph node biopsy, both the largest
and the second largest node at each station should be sampled,
especially in adenocarcinoma. If only the largest lymph node is
selected, false-negative results will occur at a rate of about 10%.
Key Words: Lung cancer, Mediastinal lymph node, Lymph node
stage, Sampling, Biopsy.
(J Thorac Oncol. 2006;1: 949–952)
Although intraoperative N-staging has traditionally beenconducted according to the surgeon’s experience, Gaer
and Goldstraw1 reported that a naked-eye assessment of nodal
staging during lung cancer surgery resulted in 11% false-
positive and 9% false-negative assessments. Even for preop-
erative N-staging, mediastinoscopy and endoscopic ultra-
sound-guided fine-needle aspiration (EUS-FNA) are reported
to have false-negative results,2–4 which could be attributable
to the small size of the biopsy specimens and also to errors in
the selection of lymph nodes. Although the largest lymph
node is usually selected in mediastinoscopy or EUS-FNA, it
has not been confirmed whether the choice of the largest is
most appropriate. Thus, it is necessary to consider whether
metastasis occurs in the largest lymph nodes. We therefore
ranked the sizes of mediastinal lymph nodes with and without
metastasis at each nodal station in non-small cell lung cancer
(NSCLC) patients with pathological N2 disease.
PATIENTS AND METHODS
Patients
From 1988 to 2005, 420 patients with lung cancer were
treated by lobectomy or pneumonectomy with systematic, not
lobe-specific, mediastinal lymph node dissection. Of these,
25 patients had mediastinal lymph node metastases (Table 1).
Ten patients who underwent neoadjuvant treatment were
excluded from the study. Whereas preoperative N-staging
was performed by computed tomography (CT) until 2004,
positron emission tomography (PET) and EUA-FNA were
added for N-staging after 2004. Our treatment strategy for
clinical N2 disease was as follows: 1) bulky N2 disease at
both superior and inferior mediastinum contraindicated sur-
gery; and 2) N2 disease with multiple affected stations
limited to either the superior or inferior mediastinum, or
bulky N2 disease at a single station, was treated by neoadju-
vant chemoradiotherapy and then surgery.
Pathological Examination
The dissected mediastinal lymph nodes were examined
histologically in formalin-fixed paraffin-embedded sections
with hematoxylin and eosin (HE) staining. The sections were
further examined by immunohistochemical staining with a
monoclonal antihuman cytokeratin antibody (DAKO Co.,
Carpinteria, CA).
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Lymph Node Stations
The lymph node nomenclature used was from the
lymph node map of Naruke et al,5 as approved by The Japan
Lung Cancer Society (Table 2).
Measurement of Lymph Node Size
The short- and long-axis diameters of all lymph nodes
were measured on HE-stained sections and ranked for each
lymph node station.
Statistical Analysis
All data were analyzed for significance using two-tailed
Student’s t tests or 2 tests. Differences at p  0.05 were
accepted as significant. All values in the text and tables are
given as mean  SD.
RESULTS
A total of 114 mediastinal lymph node stations were
resected in 25 patients. Of these, 47 stations had metastatic
lymph nodes and 67 did not. Whereas 13 of the 25 patients
had metastases at a single nodal station, the other 12 had
metastases at multiple stations. Table 3 shows the distribution
of the 47 metastatic lymph node stations in each lobe.
Whereas tumors in the upper lobes had metastases almost in
the superior mediastinum, tumors in the right lower lobe did
not show the uniform distribution of metastases, that is, four
of the five tumors had single-station metastasis in the superior
mediastinum, and the remaining one had metastases in both
the superior and inferior mediastinum. In the 47 lymph node
stations containing metastases, there were 137 lymph nodes
with metastases and 122 without (Table 4). Among the 137
metastatic lymph nodes, micrometastasis was found in three
(2%) by immunohistochemical examination. The mean short-
axis diameter of the lymph nodes with metastasis was 5  3
mm, which was significantly larger than that of those without
metastasis (3  2 mm; p  0.001). The mean long-axis
diameter of lymph nodes with metastasis was 8  5 mm,
which was significantly greater than that of those without
metastasis (5  3 mm; p  0.001).
Table 5 shows a ranking of the largest lymph nodes
with metastasis at each lymph node station. By short-axis
diameter, the largest lymph node had metastases in 44 of the
TABLE 1. Patient Characteristics
Male 17
Female 8
Mean age (year-old) 63  10
Histological subtype
Adenocarcinoma 10
Squamous cell carcinoma 8
Adenosquamous carcinoma 2
Large cell carcinoma 4
Mucoepidermoid carcinoma 1
Location of the tumor
Right upper lobe 11
Right middle lobe 1
Right lower lobe 5
Left upper lobe 6
Left lower lobe 2
Pathological tumor stage
T1N2M0 6
T2N2M0 13
T3N2M0 3
T4N2M0 3
Total 25
TABLE 2. Lymph Node Nomenclature
N2 Node N1 Node
Station Name Station Name
Superior mediastinal Hilar
1 Highest mediastinal 10 Hilar
2 Paratracheal 11 Interlobar
3 Pretracheal 12 Lobar
4 Tracheobronchial
Intrapulmonary
Aortic 13 Segmental
5 Botallo 14 Subsegmental
6 Para-aortic
Inferior mediastinal
7 Subcarinal
8 Paraesophageal
9 Pulmonary ligament
TABLE 3. Number of Mediastinal Lymph Node Stations
with Metastasis in Each Lobe
Lobe
Superior
Mediastinum
Inferior
Mediastinum (#7) Total
Right upper lobe 24 2 26
Right middle lobe 0 1 1
Right lower lobe 5 1 6
Left upper lobe 12 0 12
Left lower lobe 1 1 2
Total 42 5 47
TABLE 4. Size of the Lymph Nodes with or Without
Metastasis in the Metastatic Lymph Node Stations
Lymph Nodes
p Value
With
Metastasis
Without
Metastasis
Number 137 122
Short-axis diameter (mm) p  0.001
Mean 5  3 3  2
Range 0.5–18 0.5–11
Long-axis diameter (mm) p  0.001
Mean 8  5 5  3
Range 0.5–33 0.5–19
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47 affected lymph node stations (94%). In the remaining
three lymph node stations (6%), the largest lymph node was
clear of metastasis, but the second largest had metastasis. By
long-axis diameter, the largest lymph node had metastasis in
42 of the 47 stations (89%), and in the remaining five lymph
node stations (11%), the second largest lymph node was
involved, but the largest was not. None of the largest lymph
nodes with metastasis were smaller than the second largest
one in any of the stations when measuring both the short- and
long-axis diameters. Four of 10 patients with adenocarcinoma
(40%) had metastasis in the second largest lymph node as
measured by long-axis diameter, but not in the largest one,
which was more common than in squamous cell carcinoma,
where this occurred in one of eight cases (12.5%) (p  0.04).
DISCUSSION
The present study has demonstrated the following
points: 1) In pathological N2 disease, approximately 90% of
metastases were found in the largest lymph node at its nodal
station; 2) approximately 10% of metastasis were in the
second largest but not in the largest lymph node of each
station; 3) none of the metastatic lymph nodes were smaller
than the second largest lymph node of any nodal station; and
4) adenocarcinoma had metastasis in the second largest
lymph node, but not in the largest lymph node, more fre-
quently than squamous cell carcinoma. Therefore, examining
both the largest and second largest lymph nodes is necessary
to reach 100% sensitivity for preoperative and intraoperative
mediastinal lymph node staging. However, it should be kept
in mind that the present study measured the sizes of lymph
nodes in fixed, cut, and stained specimens, which were
smaller than their size at the moment of preoperative or
intraoperative nodal evaluation. Therefore, the absolute sizes
of lymph nodes shown in Table 5 are not applicable to
preoperative or intraoperative evaluation of lymph nodes.
The present study is concerned with the rank order of sizes of
metastatic mediastinal lymph nodes at each nodal station.
It is well known that systematic mediastinal lymph
node dissection does not increase postoperative morbidity or
mortality.6,7 However, the recent increase of clinical stage Ia
NSCLC has led to increased use of limited lung resection as
well as a reduction in mediastinal lymph node dissection.
Segmentectomy has been reported to have a similar postop-
erative prognosis as lobectomy when intraoperative frozen
sections of hilar and mediastinal lymph nodes show no
metastasis.8 Whereas the International Association for the
Study of Lung Cancer Staging Committee has determined
that the definition of stage p-N0 should be based on the
pathological findings of systematic mediastinal lymph node
dissection,9 several authors have proposed lobe-specific me-
diastinal lymph node dissection for patients with clinical
stage Ia NSCLC to minimize surgical damage10–13; that is,
the dissection of inferior mediastinal lymph node stations
could be reduced for upper lobectomy when the hilar and
superior mediastinal lymph nodes are negative for metasta-
ses, and the dissection of superior mediastinal lymph node
stations could be reduced for lower lobectomy when the hilar
and inferior mediastinal lymph nodes are negative for malig-
nancy. However, before the final decision is made on both
segmentectomy and lobe-specific mediastinal lymph node
dissection, a large number of lymph nodes need to be sub-
mitted for intraoperative frozen section. To reduce the num-
ber of lymph nodes required for this, several authors have
proposed intraoperative sentinel lymph node biopsy using
radioisotopes.14–16 However, this necessitates preoperative
injection of radioisotopes and intraoperative measurement of
the radioactivity of lymph nodes. Based on the results of the
present study, we believe that taking the largest and the
second largest lymph nodes at each station would provide a
sufficient sample of intraoperative frozen sections and would
minimize the number of intraoperative frozen sections taken.
Which lymph node stations should be submitted for
intraoperative frozen section during lung cancer surgery? In
1999, Naruke et al10 examined the distribution of lymph node
metastasis (i.e., sentinel nodes) in each lobe from data on
1815 patients with T1 NSCLC who had major lung resection
with mediastinal lymph node dissection. They concluded that,
whereas hilar lymph nodes were usually sentinel nodes in
lung cancer, the following mediastinal lymph nodes could be
sentinel nodes: #3 and/or #4 in the right upper lobe, #3 and/or
#7 in the right middle lobe, #7 in the right lower lobe, #5
and/or #6 in the left upper lobe, and #7 in the left lower lobe.
Other authors have reported similar results.17,18 The present
study, however, although showing similar results for the
upper lobes of both sides, demonstrated that four of five lung
cancers in the right lower lobe had a single metastasis at
station #3 or #4. According to our previous study of sentinel
node identification using 99mTc-tin colloid, two of eight
NSCLC in the right lower lobe had sentinel nodes in both #4
and #7.15 We consider that the lymphatic flow from the right
lower lobe could partly drain to the superior mediastinum (#3
and #4) along the main bronchus. From the previous report
and from the present study, a plan for efficient intraoperative
N-staging could be as follows: hilar lymph nodes and
lobe-specific mediastinal lymph nodes are dissected;, and
the largest and second largest lymph nodes from each
station are submitted for intraoperative frozen section. In
this way, the number of lymph nodes for frozen section
would be minimized.
Although mediastinoscopy and EUS-FNA have been
proposed for mediastinal lymph node biopsy, they are known
to have false-negative results.2–4 EUS-FNA is now the least
invasive procedure for pathological or cytological diagnosis
TABLE 5. Rank of the Size of Lymph Nodes with Metastasis
in Each Lymph Node Station
Measured by Short-Axis Diameter
Largest lymph node 44
Second largest lymph node 3
Smaller than the second one 0
Measured by long-axis diameter
Largest lymph node 42
Second largest lymph node 5
Smaller than the second 0
Total 47
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of mediastinal lymph nodes, but its sensitivity has been
reported to be 65 to 75%, which is lower than that of
mediastinoscopy.2,3 To increase the sensitivity of these bi-
opsy procedures, the present study indicated that both the
largest and the second largest lymph nodes should be targeted
to reach 100% sensitivity. If only the largest lymph node is
selected, the sensitivity will not exceed 90%.
The present study showed that adenocarcinoma may
have metastases in the second largest but not in the largest
lymph node more frequently than squamous cell carcinoma.
It is well known that the pattern of lymph node metastasis is
different between adenocarcinoma and squamous cell carci-
noma. Ohta et al19 reported that nodal micrometastasis was
detected by immunohistochemistry in 20% of patients with
adenocarcinomas 1 to 2 cm in size, whereas it was not found
in any patient with squamous cell carcinoma. Mori et al20
reported that lymph node metastases from adenocarcinoma
were of normal size more frequently than those from squa-
mous cell carcinoma. The present study indicated that both
the largest and second largest lymph nodes should be exam-
ined during N-staging, especially in adenocarcinoma.
Although it has been reported that 20 to 25% of patients
with clinical stage I disease have mediastinal lymph node
metastasis,21–23 the present study showed only 35 of 420
patients (8%) with N2 disease. Our procedure for mediastinal
lymph node dissection was systematic and yielded 114 nodal
stations in 25 patients (4.6 stations per patient) and 259 lymph
nodes from the 47 metastatic lymph node stations (5.5 lymph
nodes per station). The reason for the low number of patients
with N2 disease in the present study is probably attributable to
the institutional setting—most of the lung cancers in our patients
were found by routine CT examination, resulting in a higher rate
of early-stage NSCLC than usual.
The present study showed that an efficient selection of
mediastinal lymph nodes for N-staging is obtained by target-
ing both the largest and the second largest lymph nodes at
each station. We believe that the present data are useful not
only for intraoperative N-staging but also for preoperative
biopsy procedures.
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